LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million
Amount Raised
$40 Million
Round Type
Series A
SchlierenBiotechnology ResearchInvestors
Description
LimmaTech Biologics announced a second closing of its Series A financing, raising an additional USD 3 million from new investor Tenmile, bringing the total raised to USD 40 million. The funding will be utilized to further advance the company’s proprietary self-adjuvanting and multi-antigen vaccine technology platform and to accelerate the preclinical and clinical development of its vaccine candidate pipeline designed to tackle the global antimicrobial resistance epidemic.
Quick answer
LimmaTech Biologics raised $40 Million in a Series A round, dated February 1, 2024. Investors: Novo Holdings Repair Impact Fund, Axa Im Alts, Adjuvant Capital and Tenmile. LimmaTech Biologics is based in Schlieren, Zurich, Switzerland.
- How much did LimmaTech Biologics raise?
- LimmaTech Biologics raised $40 Million in a Series A round on February 1, 2024.
- Who invested in LimmaTech Biologics?
- Novo Holdings Repair Impact Fund, Axa Im Alts, Adjuvant Capital and Tenmile are named as investors in this round.
- What does LimmaTech Biologics do?
- LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company.
- Where is LimmaTech Biologics based and how big is it?
- LimmaTech Biologics is based in Schlieren, Zurich, Switzerland. Fundz records about 55 employees.
- Who are the decision-makers at LimmaTech Biologics?
- Fundz holds 2 contacts at LimmaTech Biologics, including the Co-Founder & CFO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology Research around the same time
Companies in the same sectors as LimmaTech Biologics that raised within 45 days of this round, from Fundz verified event records.
- Baseimmune raised $11M (Series A) on February 26, 2024.
- eFeed raised $10M (Seed) on February 21, 2024.
- VRG Therapeutics raised $15M (Series B) on February 20, 2024.
- Colipi raised $1.9M (Seed) on February 19, 2024.
- FreezeM raised $14M (Series A) on February 15, 2024.
- SingleTimeMicroneedles raised an undisclosed amount (Pre-Seed) on February 14, 2024.
Who to call at LimmaTech Biologics, and when
A new round usually means LimmaTech Biologics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day LimmaTech Biologics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at LimmaTech Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at LimmaTech Biologics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment LimmaTech Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansLimmaTech Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.